April 9, 2013
/PRNewswire/ -- Cleave Biosciences announced today it has raised
in an extension of its Series A financing from new investor
New Enterprise Associates
(NEA), bringing its Series A total to
. In the fall of 2011, Cleave raised
US Venture Partners
Astellas Venture Management
Osage University Partners
to fund the biopharmaceutical company's cancer drug discovery and development. In conjunction with the financing, NEA partner
, M.D., has joined Cleave's board of directors. Cleave will use the funds to move its lead program into clinical trials and advance its second discovery program.
Cleave is discovering novel drugs that affect protein degradation pathways. Cancer cells frequently make an excess of proteins and hence become dependent on protein degradation for their survival. By attacking key targets in these pathways, cancer cells fail to balance this excess protein synthesis with protein degradation and can no longer survive.
"The targets Cleave is pursuing have the potential to have wide therapeutic impact for people who have cancers dependent on protein degradation for their survival," said
, Ph.D., chief executive officer of Cleave Biosciences. "NEA joins us at an exciting time as we continue our progress to identify clinical candidates, as well as determine which subsets of cancers can best be addressed using the Cleave strategy."
"Cleave's approach of attacking cancer heterogeneity has rapidly moved from an academic idea to preclinical proof-of-concept and there's a reasonably high probability that the company's development programs will result in new therapeutics for patients with difficult-to-treat tumors," said
, Ph.D., partner at US Venture Partners and Cleave director.
Cleave's lead program is discovering small molecules that target p97, a central player in the ubiquitin proteasome and autophagy pathways that are intimately involved in controlling protein degradation. Targeting protein degradation has been validated by the commercial success of VELCADE® (bortezomib) and KYPROLIS® (carfilzomib) in multiple myeloma. P97 inhibition is a novel approach that has the potential to treat a wide range of cancers.